A Phase IA/IB, Two Arm, Multi-center, Open-label, Dose Escalation Study of Oral LBH589 Alone and in Combination With IV Docetaxel and Oral Prednisone in Hormone Refractory Prostate Cancer (HRPC).
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2012
At a glance
- Drugs Docetaxel; Panobinostat; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Novartis
- 25 Aug 2009 Actual patient number (16) and actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 25 Aug 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Dec 2007 Status changed from recruiting to in progress.